Company Overview and News
It's a perennial favorite, with investors and industry insiders requesting it over and over again. We wanted to provide a simple number that could be referenced and compared. Something like the GDP growth rate, which on its face is a quick look at the economy, but in reality, is a simplified summary of a nuanced subject.
LINEQ ETP.PRC LGCYP LGCYO BBPPQ LNGG VNRR BBEP WPZ ETP VNR LGCY VNRAP VNRBP VNRCP BBEPQ EEP PAA BBEPP LINE
The following slide deck was published by Linn Energy IncA in conjunction with their 2018 Q1 earnings call.
Document UNITED STATES
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
LINEQ LNGG XOM LINE
HOUSTON, April 18, 2018 (GLOBE NEWSWIRE) -- LINN Energy, Inc. (OTC:LNGG) (“LINN” or the “Company”) provides a strategic update on the previously announced separation, announces new leadership and schedules its first quarter 2018 earnings conference call.
LINEQ LNGG LINE
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Natural Gas Liquids (NGLs) Industry report offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the Cost Structure, Sales Revenue, Sales Volume, Gross Margin, market share and growth rate.
XOM LNGG CHKVP DVN BP RRL RDSB RDSA CHKDH CHKVZ SWTF CHKDG SU COP CHKDJ CHKDP SFY RYDAF CHK.PRD SU LINEQ CKRGZ RDS.B RDS.A SM SBOW RRS BP.A BP.B RGRLF CHKWZ RRC BP RGRYY CNQ CHK.WI CHK RYDBF STOHF BPAQF LINE STO
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET